UW Madison researchers have developed a novel way to manufacture large amount of micellular paclitaxel. Rather than using organic solvents to get the paclitaxel solubilized and loaded into micelles, t...
Learn More

As cancer research progresses, it is evident that single drug formulations only provide limited success. Developing combination therapies would greatly benefit patients, especially those who must fol...
Learn More

Described herein is a mono-end PEGyated functional upstream domain (FUD), pharmaceutical compositions, and its use to inhibit fibrosis such as organ fibrosis, idiopathic pulmonary fibrosis and fibrosi...
Learn More

The present technology relates generally to oligolactic acid conjugates of paclitaxel, rapamycin, selumetinib, and other anticancer agents, micelle compositions containing such conjugates and methods ...
Learn More

Many drugs that are potentially efficacious for treating diseases such as cancer have limited usefulness because they are relatively insoluble and/or toxic. Polymeric micelles can serve as vehicles fo...
Learn More

Two-drug combinations of paclitaxel and rapamycin (an mTOR inhibitor) as well as paclitaxel and 17-AAG (an enhanced version of geldanamycin and Hsp90 inhibitor) have progressed into human clinical tri...
Learn More

PTX, DTX, rapamycin and selumetinib are potent chemotherapeutic agents useful in the treatment of a variety of cancers. Due to their limited water solubility, PTX and DTX are commonly formulated for p...
Learn More